SureNano Science Ltd (TSE:SURE)
:SURE
Top Page
SureNano Science Ltd
(SURE)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.28
▼(-7.67% Downside)
Action:ReiteratedDate:03/10/26
The score is driven primarily by very weak financial performance (no recent revenue, ongoing losses and cash burn, and negative equity). Technicals add further caution with a generally bearish trend and negative MACD, only slightly tempered by oversold-leaning RSI/Stoch readings. Valuation provides limited support due to the company being loss-making and no dividend yield data.
Positive Factors
Low leverage (no reported debt)
The absence of reported debt reduces near-term refinancing and interest burden risks, preserving financial flexibility to prioritize operations or R&D. Over 2–6 months this improves survival odds and gives management time to pursue restructuring or new capital without immediate default pressure.
Negative Factors
Zero recent revenue
Sustained absence of revenue for multiple years prevents absorption of fixed costs and eliminates operational self-sufficiency. Over the medium term this undermines business viability, forces reliance on financing, and weakens prospects for rebuilding scale or recovering previously healthy gross margins.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage (no reported debt)
The absence of reported debt reduces near-term refinancing and interest burden risks, preserving financial flexibility to prioritize operations or R&D. Over 2–6 months this improves survival odds and gives management time to pursue restructuring or new capital without immediate default pressure.
Read all positive factors
SureNano Science Ltd (SURE) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$9.83M
Dividend YieldN/A
Average Volume (3M)666.00
Price to Earnings (P/E)―
Beta (1Y)-1.72
Revenue GrowthN/A
EPS Growth91.27%
CountryCA
EmployeesN/A
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-0.01
Shares Outstanding33,907,800
10 Day Avg. Volume950
30 Day Avg. Volume666
Financial Highlights & Ratios
PEG Ratio0.37
Price to Book (P/B)-21.52
Price to Sales (P/S)0.00
P/FCF Ratio-10.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SureNano Science Ltd Business Overview & Revenue Model
Company Description
SureNano Science Ltd. operates as a nanotechnology supply company in Canada and Colorado, the United States. The company distributes SureNano surfactant, a ready-to-mix food-grade compound that provides the base for high performance hemp and canna...
How the Company Makes Money
null...
SureNano Science Ltd Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
14
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Mar 2024 | Jun 2023 | Jun 2022 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 18.00K | 36.00K |
| Gross Profit | -1.88K | -2.50K | -2.50K | -3.75K | 16.51K | 34.66K |
| EBITDA | -407.27K | -57.09K | -277.39K | -380.27K | -1.12M | -81.59K |
| Net Income | -226.77K | -59.59K | -279.89K | -384.02K | -1.12M | -82.51K |
Balance Sheet | ||||||
| Total Assets | 1.20M | 54.27K | 153.11K | 317.61K | 686.44K | 966.81K |
| Cash, Cash Equivalents and Short-Term Investments | 1.17M | 23.49K | 134.80K | 276.99K | 667.09K | 929.01K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 34.16K | 134.04K | 173.29K | 57.90K | 36.49K | 17.32K |
| Stockholders Equity | 1.17M | -79.77K | -20.18K | 259.71K | 649.95K | 949.49K |
Cash Flow | ||||||
| Free Cash Flow | -208.53K | -161.31K | -142.19K | -403.63K | -669.76K | -102.99K |
| Operating Cash Flow | -208.53K | -161.31K | -142.19K | -383.63K | -669.76K | -102.99K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -6.47K | 0.00 | 0.00 |
| Financing Cash Flow | 1.39M | 50.00K | 0.00 | 0.00 | 407.85K | 1.03M |
SureNano Science Ltd Technical Analysis
Positive
0.30
Price Trends
0.30
Negative
0.25
Positive
0.19
Positive
Market Momentum
>-0.01
Negative
51.62
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SURE, the sentiment is Positive. The current price of 0.3 is above the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.30, and above the 200-day MA of 0.19, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.62 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:SURE.
SureNano Science Ltd Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | C$2.95B | 22.34 | 26.65% | ― | 30.36% | 181.15% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
48 Neutral | C$898.54M | -46.51 | -1.58% | 2.55% | 8.04% | -195.66% | |
44 Neutral | C$242.61M | -3.44 | -414.40% | ― | 6.29% | -3.71% | |
42 Neutral | C$14.03M | -2.61 | -86.94% | ― | -15.84% | -375.96% | |
42 Neutral | C$105.22M | -4.53 | -64.75% | ― | ― | 56.03% | |
41 Neutral | C$9.83M | -6.54 | ― | ― | ― | 91.27% |
* Basic Materials Sector Average
TSE:SURE
SureNano Science Ltd
0.29
0.21
262.50%
TSE:CNO
California Nanotechnologies
0.29
-0.67
-69.48%
TSE:NANO
Nano One Materials
0.88
0.19
27.54%
TSE:VNP
5N Plus
33.15
27.82
521.95%
TSE:NEO
Neo Performance Materials Inc
21.60
13.01
151.31%
TSE:GMG
Graphene Manufacturing Group Ltd
2.06
1.38
202.94%
SureNano Science Ltd Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
SureNano Buys GlucaPharm to Drive Next-Generation GLP-1 Drug Push
Positive
Feb 23, 2026
SureNano Science Ltd. has completed the acquisition of GlucaPharm Inc., gaining control of GEP44, a patented, second-generation GLP peptide that has shown significant weight-loss and blood-glucose benefits in preclinical studies with fewer gastroi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.